Trexquant Investment LP Purchases 103,114 Shares of Janux Therapeutics, Inc. $JANX

Key Points

• Trexquant Investment LP's stake in Janux Therapeutics increased by 156.6% in the first quarter, bringing their total ownership to 168,972 shares valued at approximately $4.56 million.
• Other hedge funds, such as Paradigm Biocapital and Wellington Management, have also significantly increased their positions in Janux Therapeutics, reflecting strong institutional interest in the company.
• Janux Therapeutics has received positive analyst ratings, with a consensus "Buy" and a price target of $86.90, despite the stock recently experiencing a decline of 1.4% to $22.72.

Trexquant Investment LP increased its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 156.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 168,972 shares of the company's stock after buying an additional 103,114 shares during the quarter. Trexquant Investment LP owned 0.29% of Janux Therapeutics worth $4,562,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Allspring Global Investments Holdings LLC increased its holdings in Janux Therapeutics by 54.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 9,033 shares of the company's stock worth $244,000 after purchasing an additional 3,168 shares in the last quarter. New York State Common Retirement Fund increased its holdings in Janux Therapeutics by 3.0% in the 1st quarter. New York State Common Retirement Fund now owns 16,435 shares of the company's stock worth $444,000 after purchasing an additional 471 shares in the last quarter. Millennium Management LLC acquired a new position in Janux Therapeutics in the 4th quarter worth about $6,216,000. California State Teachers Retirement System increased its holdings in Janux Therapeutics by 82.2% in the 4th quarter. California State Teachers Retirement System now owns 36,735 shares of the company's stock worth $1,967,000 after purchasing an additional 16,575 shares in the last quarter. Finally, KBC Group NV acquired a new position in Janux Therapeutics in the 1st quarter worth about $66,000. Institutional investors and hedge funds own 75.39% of the company's stock.

Wall Street Analysts Forecast Growth

JANX has been the subject of a number of recent research reports. Raymond James Financial initiated coverage on Janux Therapeutics in a report on Friday, July 11th. They issued an "outperform" rating and a $65.00 target price for the company. Piper Sandler initiated coverage on Janux Therapeutics in a report on Monday, August 18th. They issued an "overweight" rating and a $42.00 target price for the company. Finally, Guggenheim initiated coverage on Janux Therapeutics in a report on Wednesday. They issued a "buy" rating and a $72.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, Janux Therapeutics currently has an average rating of "Buy" and a consensus price target of $85.55.

Janux Therapeutics Stock Performance

Shares of JANX stock traded up $0.04 on Friday, hitting $23.98. The company had a trading volume of 429,791 shares, compared to its average volume of 684,759. The firm has a market cap of $1.44 billion, a P/E ratio of -13.32 and a beta of 2.84. The stock's 50-day moving average is $24.53 and its two-hundred day moving average is $26.68. Janux Therapeutics, Inc. has a twelve month low of $21.97 and a twelve month high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.07). Equities research analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.